Can the President Impose Tariffs on Generic Drugs?

Tariffs feel like a presidential weapon because presidents announce them like one. A rate. A date. A target. A promise that factories will come home.

But constitutionally, tariffs start as a legislative power. Article I gives Congress authority to “lay and collect Taxes, Duties, Imposts and Excises,” and to “regulate Commerce with foreign Nations.”

The complicated part is the modern add-on: Congress has repeatedly written statutes that let the president trigger tariffs under specified conditions. So the real question is rarely “can a president do this?” It is “did Congress already authorize something like this, and if so, how far does that authorization go?”

This matters for any proposed schedule that keeps a tariff at 0% for a time and then ramps it up later, including a proposal aimed at generic drugs. The legal answer depends less on the politics and more on the statute an administration would cite to do it.

Who sets tariffs?

The Constitution’s design is intentionally lopsided here. If you want to raise money at the border or make imports more expensive to shape the economy, Congress is supposed to be in the driver’s seat. Tariffs are both revenue and regulation, and Article I assigns both to the legislature.

So where does the president come in?

• Article II power gives the president the duty to execute the laws and to conduct foreign relations. It does not, by itself, create a free-standing tariff power.
• Delegation statutes are the bridge. Congress can write a law that says, in effect: if the president finds X about a foreign country or a market condition, the president may impose Y trade restriction.

This is why debates about “unilateral tariffs” almost always turn into debates about which statute is being used. The Constitution asks: is the president executing a law Congress wrote, or creating a new one?

What Section 338 does

Where it lives: Section 338 is part of the Tariff Act of 1930 and is codified in the U.S. Code at 19 U.S.C. § 1338. It is an older, retaliation-focused delegation: if a foreign country discriminates against U.S. commerce, the president can respond by increasing barriers against that country’s imports.

In broad strokes, Section 338 is built around three parts:

• A country-specific trigger. The statute focuses on discriminatory treatment by a foreign country that burdens U.S. commerce. The exact statutory wording matters, including how the discrimination is framed in relation to U.S. goods and U.S. vessels.
• A presidential finding. The statute expects the president to determine that the discrimination exists before acting, and in practice that means the administration needs a defensible factual record.
• A retaliatory remedy. The remedy is aimed at imports from the discriminating country.

Most importantly, Section 338 is not a general “reshore manufacturing” tool. It is a retaliation tool. The legal theory is not “we want more domestic production,” but “a foreign government is discriminating, and we are responding.”

What it authorizes: As commonly described, Section 338 authorizes the president to proclaim new or additional duties up to 50 percent ad valorem on articles imported from the discriminating country, and it also provides an escalation mechanism up to prohibiting importation if the discrimination persists. Because Section 338 is rarely used in modern practice compared with tools like Sections 232 and 301, any serious plan would need to track the current codified language closely, including the conditions and sequencing for moving from additional duties to prohibition.

Can it cover drug imports?

Potentially, yes, but it depends on the why and the how.

1) The “what” can be broad

Trade delegation statutes often do not care whether the import is steel, cars, or pills. If a statute authorizes duties on imported “articles” from a target country, generic drugs can fit. Still, the on-the-ground administration is product-specific. Customs and Border Protection has to apply HTSUS classifications, valuation rules, and country-of-origin determinations, and those details can drive real disputes, especially where other regimes such as antidumping and countervailing duties are also in play.

2) The “why” can be narrow

Section 338 is not a general industrial policy clause. A Section 338 proclamation is strongest when it clearly identifies:

• the foreign country or countries covered,
• the specific discriminatory measure or practice,
• how that discrimination burdens U.S. commerce under the statute’s terms, and
• why the chosen response is an appropriate retaliation under the statute.

A concrete example: suppose Country X adopts a pharmaceutical reimbursement rule or import licensing practice that, in effect, disadvantages U.S.-made drugs or U.S. drug exporters while favoring domestic producers or certain third countries. A Section 338 action that targets imports from Country X, and that is justified as retaliation for that documented discriminatory treatment, maps more naturally onto Section 338’s design than a worldwide generic-drug tariff justified mainly by reshoring.

If a tariff is framed primarily as a penalty designed to force reshoring, challengers will argue the administration is using a retaliation statute for a different policy goal.

3) The “how” has to match the statute

Even where a statute allows higher duties, the practical legal question is whether the action still resembles what Congress authorized or instead becomes a de facto new tariff code. Section 338, as commonly summarized, has a built-in structure: additional duties up to a stated ceiling, and a separate, more extreme step of prohibition if discrimination continues. That structure can help a president defend a measured retaliatory tariff as exactly what Congress wrote. It can also constrain an attempt to impose sweeping, escalating rates that do not fit the statute’s stated limits.

Country-based fit

This is where proposed “generic drug tariffs” can run into a statutory fit problem.

Section 338 is framed around discrimination by a foreign country and retaliation against that country’s imports. A broad product-wide tariff that hits generic drugs from everywhere, or that is justified mainly as reshoring regardless of what any foreign government has done, reads less like retaliation and more like industrial policy.

That does not mean a drug tariff is impossible. It means the legal pathway matters. A country-targeted drug tariff linked to a concrete, documented foreign discriminatory measure is easier to defend under Section 338 than a blanket worldwide product tariff with a domestic supply-chain rationale.

Other tools

When people think of modern presidential tariffs, they usually think of other statutes more than Section 338. Each has its own trigger and vulnerabilities:

• Section 232 of the Trade Expansion Act (1962): permits tariffs for national security, after a Commerce Department investigation.
• Section 301 of the Trade Act (1974): permits tariffs responding to unfair trade practices, typically after an investigation and findings by the U.S. Trade Representative. For pharmaceuticals, this is often where disputes about discriminatory reimbursement, market access barriers, or IP-related practices are argued.
• Antidumping and countervailing duty laws: a different system that can produce very high effective rates in particular cases, but only after agency investigations and findings of dumping and or subsidization, plus injury determinations.
• IEEPA (1977): emergency economic powers often used for sanctions. Its use for tariffs is contested. The recurring interpretive fault line is whether IEEPA authorizes something that looks like a customs “duty” imposed through the tariff schedule, or whether it is limited to regulating transactions and property interests during a declared emergency.

Why mention these in a generic-drug tariff story? Because the legal justification determines the legal fight. A tariff framed as national security will be litigated through Section 232 concepts and procedures. A tariff framed as retaliation for discriminatory pharmaceutical treatment abroad sounds like Section 338. A tariff framed as reshoring is industrial policy, which generally needs clearer congressional authorization than a retaliation statute provides.

Delegation has limits

The Constitution does not forbid Congress from delegating discretion to the executive. The Supreme Court has long upheld broad delegations so long as Congress supplies an “intelligible principle,” meaning some guiding standard for how the executive should use the power.

But trade delegation has two stress points that show up again and again in litigation:

• Statutory fit: did the president follow the procedures and satisfy the triggers Congress required, such as findings, country targeting, and product definitions?
• Separation of powers concerns: if a statute is read to allow essentially unlimited tariff power, challengers may argue Congress handed away its Article I authority without meaningful limits.

Courts have historically been reluctant to strike down trade delegations outright, though outcomes vary by statute and by the administrative record. Still, as tariff rationales expand, the pressure increases. The bigger the tariff, the more it starts to look like lawmaking by proclamation. And that is exactly what Article I was written to prevent.

Do you need a new law?

Not always. If an existing statute authorizes the action and the administration checks every procedural box, a new act of Congress is not required.

But when a tariff is ambitious, novel, or economically sweeping, the fight usually becomes less about “tariffs are unconstitutional” and more about “this tariff is not authorized by the statute you cited.” Under Section 338 in particular, challengers will test whether the government actually established discrimination in the way the statute requires, and whether the remedy fits the statutory structure.

How a lawsuit works

If a tariff like this is imposed, a challenge is likely to move quickly through trade-specific courts, not a random district court. Importers and affected companies often litigate in the U.S. Court of International Trade, with appeals to the U.S. Court of Appeals for the Federal Circuit.

In that posture, the case tends to look less like a political debate and more like a checklist: what statute was invoked, what findings were made, what record supports them, what countries and products were covered, and whether the action matches the authority Congress actually delegated.

Other limits still apply

Administrative law

Even when the president acts through a proclamation, implementation runs through agencies. Customs classification, scope definitions, exclusions, effective dates, and enforcement instructions can all produce administrative law challenges, depending on the form of the agency action and how it affects regulated parties.

Due process, indirectly

Import tariffs are not usually litigated as individual-rights violations. But companies can raise due process styled arguments about arbitrary enforcement, lack of notice, or inconsistent classifications, especially when a measure operates like a penalty regime tied to investment behavior or opaque eligibility criteria.

Trade commitments and retaliation

International trade commitments do not override the Constitution’s allocation of power, but they can create binding international obligations and real-world consequences. If the United States imposes a sweeping drug tariff, other countries can respond with their own tariffs, dispute settlement, or targeted pressure on politically sensitive exports. In the drug context, that practical retaliation can show up as higher input costs, disrupted supply chains, or countermeasures aimed at other U.S. industries.

The constitutional bottom line

The president does not have a free-standing constitutional power to impose tariffs on generic drugs. Congress does.

But Congress can delegate tariff authority, and it has. Section 338, codified at 19 U.S.C. § 1338, is one possible source, designed for retaliation against discriminatory foreign treatment. If a generic-drug tariff is justified and structured within the statute’s trigger and limits, it can be legally defensible without new legislation.

If it is justified primarily as a domestic industrial policy penalty, the legal question sharpens: is the president executing a trade statute, or relying on an aggressive reading of executive discretion and a creative use of a retaliation tool?

That is the real hinge. Not whether tariffs are powerful. They are. The hinge is who holds the power, and what Congress actually handed over.

Quick FAQ

Can a president impose a 200% tariff?

A rate that high is not automatically unconstitutional. The key is whether an existing statute authorizes the rate and whether the administration followed the statute’s required findings and procedures. Under Section 338 as commonly summarized, additional duties are capped at 50 percent ad valorem, with prohibition as the separate escalation mechanism if discrimination persists. Very high effective rates have more commonly appeared in other legal regimes, such as antidumping and countervailing duty cases, which operate through their own statutes and investigative findings.

Are tariffs the same as taxes?

They are a type of tax. The Constitution treats duties and imposts as congressional revenue powers, even when tariffs are used primarily as regulation.

What would stop a generic-drug tariff?

Congress could pass a law limiting or rescinding delegated authority, though presidential veto politics matter. Courts could also block a tariff if they find the statutory trigger was not satisfied, required procedures were not followed, or the measure does not match the authority Congress delegated.